Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7306 to 7320 of 7708 results

  1. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development [GID-TA11189] Expected publication date: TBC

  2. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

  3. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

  4. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

  5. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development [GID-TA11443] Expected publication date: TBC

  6. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

  7. QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)

    This advice has been updated and replaced by NICE diagnostics guidance 43.

  8. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This medtech innovation briefing (MIB) has been updated and replaced by NICE diagnostics guidance 41.

  9. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued [GID-TA11396]

  10. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

    In development [GID-TA11588] Expected publication date: TBC

  11. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE diagnostics guidance 37.

  12. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development [GID-TA10826] Expected publication date: TBC

  13. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development [GID-TA11044] Expected publication date: TBC

  14. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development [GID-TA11344] Expected publication date: TBC

  15. Utrasound-guided foam sclerotherapy for varicose veins (IPG314)

    This guidance has been updated and replaced by NICE interventional procedure guidance 440.